Immunocore's Brenetafusp Phase 1 Data Shows 50% Objective Response Rate
0h ago|3 min readQuick Read
Fazen Markets Editorial Desk
Collective editorial team · methodology
immunocorebrenetafusp
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Immunocore Holdings plc announced Phase 1 clinical trial data for its investigational drug brenetafusp on May 31, 2026. The T cell engager candidate, targeting advanced melanoma, demonstrated a 50% objective response rate among evaluable patients. The data release provides the first clinical validation for the company's next-generation ImmTAC platform. Investor focus now shifts to the drug's safety profile and its competitive positioning within the crowded immuno-oncology landscape.
Immuno-oncology remains one of the most active and valuable therapeutic areas, with the global market projected to exceed $130 billion by 2028. Melanoma treatment has been revolutionized by immunotherapies, but a significant portion of patients still fail to respond or develop resistance to existing checkpoint inhibitors. The last major advancement came in late 2025 when Merck's Keytruda received an additional approval in adjuvant settings, pushing its annual sales above $30 billion.
The current macro backdrop for biotech is cautiously optimistic, with the XBI Biotech ETF trading near $95, up 12% year-to-date but still below its 2021 peak. Immunocore's data drop occurs during a period of heightened investor scrutiny on clinical data readouts, as the sector demands clearer paths to profitability. Brenetafusp's mechanism of action, which redirects T cells to target cancer, represents a direct challenge to established players.
Brenetafusp's Phase 1 trial enrolled 42 patients with advanced cutaneous melanoma who had progressed on prior anti-PD-1 therapy. The objective response rate of 50% was observed in the 24 evaluable patients receiving the recommended Phase 2 dose. This includes two complete responses and ten partial responses.
Disease control was achieved in 70% of patients at the 16-week assessment. The most common treatment-related adverse events were Grade 1-2 cytokine release syndrome, occurring in 60% of patients, and rash in 45%. Only 5% of patients experienced Grade 3 events requiring dose modification. The median duration of response has not yet been reached, with responses ongoing in 10 of 12 responders at the data cutoff.
| Metric | Brenetafusp (RP2D) | Industry Benchmark |
|---|---|---|
| Objective Response Rate | 50% | 15-25% |
| Disease Control Rate | 70% | 35-50% |
This response rate substantially exceeds the 15-25% benchmark for therapies in similar post-checkpoint patient populations.
Immunocore's [IMCR] stock is the primary beneficiary, with potential for significant revaluation based on expanded market opportunity. Positive data strengthens the company's negotiating position for potential partnership deals. Competitors with late-stage melanoma assets face increased competitive threat, particularly Iovance Biotherapeutics [IOVA] with its TIL therapy and Regeneron [REGN] with its LIBTAYO program.
Diagnostic companies specializing in companion tests for immuno-oncology, such as Foundation Medicine (owned by Roche), may see increased demand as brenetafusp's development progresses. The data also provides validation for the broader T cell engager platform approach, potentially benefiting companies like Biotherapeutics Inc. and other developers of bispecific antibodies.
The primary limitation of this data is the small patient population typical of Phase 1 studies. The durability of responses and overall survival data remain unknown. Institutional investors are likely accumulating long positions in IMCR while maintaining hedges through short positions in larger cap oncology names that face increased competition.
Investors should monitor the Phase 2 trial initiation, expected by Q4 2026, which will provide a clearer picture of efficacy in a larger cohort. The American Society of Clinical Oncology (ASCO) Annual Meeting, beginning June 5, 2026, may feature additional subgroup analyses from this dataset.
Key levels to watch for IMCR stock include the $45 resistance level, a break above which could signal sustained momentum. Regulatory feedback on accelerated approval pathways will be crucial; the company may file for Breakthrough Therapy Designation by end of year. Failure to replicate these response rates in larger trials would significantly de-risk the investment thesis.
Brenetafusp is a bispecific T cell engager that binds both CD3 on T cells and PRAME on cancer cells. This mechanism redirects the patient's own T cells to recognize and kill tumor cells expressing the PRAME antigen, which is found in many melanoma cases but not in most healthy tissues.
Retail investors should note that Phase 1 data often creates volatility. While the 50% response rate is encouraging, the stock may remain speculative until larger Phase 2 data confirms these results. The company's cash runway through mid-2027 reduces near-term dilution risk.
Approximately 15% of oncology drugs that enter Phase 1 trials eventually receive FDA approval. Drugs demonstrating response rates above 40% in early trials, particularly in hard-to-treat populations, have historically shown higher likelihood of eventual approval, with some analyses suggesting a probability exceeding 25%.
Immunocore's brenetafusp demonstrates competitive efficacy in a patient population with limited treatment options.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.